X0508 4 2023-08-10 0 0001826667 TriSalus Life Sciences, Inc. TLSI 0001251956 MATLIN DAVID J 6272 W. 91ST AVENUE WESTMINSTER CO 80031 1 0 0 0 0 Common Stock 2023-08-10 4 J 0 931904 A 931904 D Redeemable Warrants 11.50 2023-08-10 4 J 0 1240518 0.00 A 2023-09-09 Common Stock 1240518 1240518 D Stock Option (right to buy) 11.34 2023-08-10 4 A 0 35000 0.00 A 2023-08-08 Common Stock 35000 35000 D Series A Preferred Stock 10.00 2023-08-10 4 A 0 100000 10.00 A Common Stock 100000 100000 D Represents shares of Common Stock received as a pro rata distribution for no consideration from MedTech Acquisition Sponsor LLC ("Sponsor") in accordance with the terms of the Sponsor's limited liability company agreement. In prior reports, the Reporting Person reported beneficial ownership of 6,250,000 shares of Issuer's Common Stock held by the Sponsor, of which the Reporting Person is a managing member. Represents warrants received as a pro rata distribution for no consideration from the Sponsor in accordance with the terms of the Sponsor's limited liability company agreement. The redeemable warrants expire on August 10, 2028, or earlier upon redemption or liquidation. The shares subject to this stock option vest in three equal annual installments from the vesting commencement date of August 10, 2023, subject to the Reporting Person's continued service with the Issuer on each respective vesting date. The Series A Convertible Preferred Stock ("Preferred Stock") is convertible, in whole or in part, into 100,000 shares of Common Stock of the Issuer (based on an initial conversion price of $10.00 per share, which is subject to adjustment upon the occurrence of certain events, the "Conversion Price") at any time, at the Reporting Person's election. The number of shares of the Issuer's Common Stock received per share of Preferred Stock upon conversion equals the sum of (A) $10.00 (as adjusted upon the occurrence of certain events) and (B) any accrued, unpaid annual dividends, divided by the Conversion Price, with cash in-lieu of fractional shares. All then outstanding shares of Preferred Stock are automatically converted into shares of the Issuer's Common Stock on August 10, 2027. /s/ Sean Murphy, Attorney-in-Fact for David J. Matlin 2023-08-14